Contineum Therapeutics, Inc.
CTNM
$9.80
-$0.59-5.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.78% | 104.37% | 128.72% | 95.38% | 62.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.58% | 82.38% | 76.18% | 60.79% | -1.08% |
| Operating Income | -63.58% | -82.38% | -76.18% | -60.79% | -128.11% |
| Income Before Tax | -78.04% | -89.97% | -83.67% | -61.20% | -121.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.04% | -89.97% | -87.48% | -64.25% | -121.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.04% | -89.97% | -87.48% | -64.25% | -121.68% |
| EBIT | -63.58% | -82.38% | -76.18% | -60.79% | -128.11% |
| EBITDA | -63.75% | -82.71% | -76.08% | -60.88% | -127.92% |
| EPS Basic | -60.59% | 82.60% | -10.63% | 85.16% | -108.08% |
| Normalized Basic EPS | -60.56% | 82.60% | 83.34% | 85.44% | -102.09% |
| EPS Diluted | -60.59% | 82.60% | -10.63% | 85.13% | -121.49% |
| Normalized Diluted EPS | -60.56% | 82.60% | 83.34% | 85.44% | -104.10% |
| Average Basic Shares Outstanding | 10.88% | 991.93% | 1,002.58% | 1,006.86% | 918.87% |
| Average Diluted Shares Outstanding | 10.88% | 991.93% | 1,002.58% | 1,006.86% | 419.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |